Bambusa Therapeutics, a Boston, MA-based biotechnology company, raised a Series A financing of approximately $90M.
The round was led by new investor RA Capital Management, with participation from new investors including Janus Henderson Investors, Redmile Group, Invus, and ADAR1 Capital Management. All existing investors also participated.
In conjunction with the financing, Dr. Derek DiRocco, Partner at RA Capital Management, will join Bambusa’s Board of Directors.
The company intends to use the funds to support the advancement of its lead programs through Phase I trials and drive further pipeline development.
Led by Founder and CEO Shanshan Xu, Bambusa Therapeutics is a biotechnology company specializing in developing transformative inflammatory and immunological therapeutics.
Since its founding in May 2024, Bambusa has built a pipeline of long-acting bispecific antibodies, leveraging validated targets and biological synergy to create best-in-disease therapies for I&I indications. Two of Bambusa’s four programs are on track to enter the clinic in Q1 2025 and mid-2025, respectively.
- BBT001, the lead candidate, is a bispecific antibody incorporating a number of features intended to supplant the current standard of care for a range of dermatological conditions.
- BBT002 is a bispecific antibody created as a “platform in a molecule” with applications across respiratory, dermatology, and gastroenterology indications.
- Additional development candidates, BBT003 and BB004, also have best-in-disease potential in the inflammatory bowel diseases and rheumatological indications.
FinSMEs
18/02/2025